Research graph
References from Circulating biomarkers to monitor cancer progression and treatment. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1158/0008-5472.can-12-2217
10.1158/0008-5472.can-12-2217 · External reference
Tumor heterogeneity
1984 · External reference
Generation of phenotypic diversity and progression in metastatic tumor cells
10.1007/bf00047691 · 1984 · External reference
10.1016/s1357-4310(00)01756-1
10.1016/s1357-4310(00)01756-1 · External reference
10.1056/nejmoa1113205
10.1056/nejmoa1113205 · External reference
10.1038/nature08989
10.1038/nature08989 · External reference
10.1016/j.trecan.2015.10.006
10.1016/j.trecan.2015.10.006 · External reference
A case of cancer in which cells similar to those in the tumours were seen in the blood after death
1869 · External reference
The prognostic value of cytologic studies of the blood of patients with bronchogenic carcinoma
10.1016/s0022-5223(19)33244-1 · 1965 · External reference
Appearance of cancer cells in the blood stream of gastric cancer patients. Its significance in prognosis
1965 · External reference
Survival after resection of bronchial carcinomas. Significance of tumour cells in the blood
10.1016/s0140-6736(66)90003-1 · 1966 · External reference
Unresolved reference
1948 · External reference
10.1016/0277-5379(87)90266-5
10.1016/0277-5379(87)90266-5 · External reference
10.1023/a:1006260319913
10.1023/a:1006260319913 · External reference
Circulating DNA in higher organisms cancer detection brings back to life an ignored phenomenon
2005 · External reference
10.1126/scitranslmed.3007094
10.1126/scitranslmed.3007094 · External reference
10.1016/j.cell.2015.11.050
10.1016/j.cell.2015.11.050 · External reference
10.1038/nmeth898
10.1038/nmeth898 · External reference
10.1038/nmeth850
10.1038/nmeth850 · External reference
10.1373/clinchem.2013.206359
10.1373/clinchem.2013.206359 · External reference
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma
2012 · External reference
10.1016/j.ymeth.2009.12.006
10.1016/j.ymeth.2009.12.006 · External reference
10.1371/journal.pone.0023418
10.1371/journal.pone.0023418 · External reference
10.1038/nm.3519
10.1038/nm.3519 · External reference
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
10.18632/oncotarget.5788 · 2015 · External reference
10.1093/annonc/mdv177
10.1093/annonc/mdv177 · External reference
10.1038/nbt.2897
10.1038/nbt.2897 · External reference
10.1056/nejmoa1213261
10.1056/nejmoa1213261 · External reference
10.1126/scitranslmed.3000702
10.1126/scitranslmed.3000702 · External reference
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors
10.1002/gcc.20815 · 2010 · External reference
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
10.18632/oncotarget.5256 · 2015 · External reference
Origin and prognostic value of circulating KRAS mutations in lung cancer patients
10.1016/j.canlet.2007.03.008 · 2007 · External reference
10.1038/nature12065
10.1038/nature12065 · External reference
Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
10.1371/journal.pone.0043393 · 2012 · External reference
Circulating cell-free DNA in serum as a biomarker of colorectal cancer
10.1136/jclinpath-2013-201521 · 2013 · External reference
10.1007/s00268-004-7366-8
10.1007/s00268-004-7366-8 · External reference
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
10.1016/j.ejso.2010.05.014 · 2010 · External reference
K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer
10.1097/mpa.0b013e3182289118 · 2012 · External reference
10.1002/cncr.29364
10.1002/cncr.29364 · External reference
10.1158/1078-0432.ccr-15-0321
10.1158/1078-0432.ccr-15-0321 · External reference
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy
10.1158/1078-0432.ccr-06-2120 · 2007 · External reference
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
10.1158/1078-0432.ccr-03-0384 · 2004 · External reference
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
10.1200/jco.2006.06.9104 · 2006 · External reference
10.1093/annonc/mdv272
10.1093/annonc/mdv272 · External reference
Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses
10.1158/1078-0432.ccr-15-1031 · 2015 · External reference
10.1371/journal.pone.0145754
10.1371/journal.pone.0145754 · External reference
Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors
10.1373/clinchem.2014.230235 · 2015 · External reference
10.1038/nm.3564
10.1038/nm.3564 · External reference
Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients
2012 · External reference
Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation
10.1196/annals.1368.040 · 2006 · External reference
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
10.1016/s0140-6736(10)61268-8 · 2010 · External reference
Survival of prostate cancer patients in central and northern Denmark, 1998–2009
10.2147/clep.s20625 · 2011 · External reference
10.1093/jnci/djp001
10.1093/jnci/djp001 · External reference
Early lung cancer action project: overall design and findings from baseline screening
10.1016/s0140-6736(99)06093-6 · 1999 · External reference
Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients
10.1016/s0024-3205(96)00576-0 · 1996 · External reference
Analysis of cell-free Epstein–Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma
10.1093/clinchem/45.8.1292 · 1999 · External reference
Detection of tumor messenger RNA in the serum of patients with malignant melanoma
1999 · External reference
Free circulating mRNA in plasma from breast cancer patients and clinical outcome
10.1016/j.canlet.2008.01.008 · 2008 · External reference
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications
10.1371/journal.pone.0008173 · 2009 · External reference
Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics
10.1371/journal.pone.0043470 · 2012 · External reference
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients
10.1186/bcr1760 · 2007 · External reference
Circulating lncRNAs associated with occurrence of colorectal cancer progression
2015 · External reference
Plasma extracellular RNA profiles in healthy and cancer patients
10.1038/srep19413 · 2016 · External reference
10.1038/nrm3089
10.1038/nrm3089 · External reference
RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer
10.18632/oncotarget.2476 · 2014 · External reference
10.1016/s0092-8674(02)00718-3
10.1016/s0092-8674(02)00718-3 · External reference
10.1038/leu.2012.111
10.1038/leu.2012.111 · External reference
Elevated snoRNA biogenesis is essential in breast cancer
10.1038/onc.2013.89 · 2014 · External reference
Small nucleolar RNA signatures of lung tumor-initiating cells
10.1186/1476-4598-13-104 · 2014 · External reference
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
10.1186/1476-4598-9-198 · 2010 · External reference
10.3390/ijms161023651
10.3390/ijms161023651 · External reference
10.1038/nrg2521
10.1038/nrg2521 · External reference
LncRNADisease: a database for long-non-coding RNA-associated diseases
10.1093/nar/gks1099 · 2013 · External reference
10.1101/gr.135350.111
10.1101/gr.135350.111 · External reference
10.1101/gr.132159.111
10.1101/gr.132159.111 · External reference
The clinical relevance of long non-coding RNAs in cancer
10.3390/cancers7040884 · 2015 · External reference
Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer
10.1007/s13277-014-2807-y · 2015 · External reference
10.1016/j.ejca.2013.04.026
10.1016/j.ejca.2013.04.026 · External reference
Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma
10.18632/oncotarget.2934 · 2015 · External reference
Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC
10.1159/000430226 · 2015 · External reference
Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma
10.1186/1476-4598-14-3 · 2015 · External reference
10.1016/j.ccell.2016.03.004
10.1016/j.ccell.2016.03.004 · External reference
Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer
10.1177/1947601913499020 · 2013 · External reference
Circulating long non-coding RNAs in plasma of patients with gastric cancer
2013 · External reference
Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls
10.1002/ijc.29484 · 2015 · External reference
10.1016/s0092-8674(04)00045-5
10.1016/s0092-8674(04)00045-5 · External reference
10.1038/nrc3932
10.1038/nrc3932 · External reference
10.1093/jb/mvq113
10.1093/jb/mvq113 · External reference
10.1016/j.cell.2009.01.002
10.1016/j.cell.2009.01.002 · External reference
The Argonaute protein family
10.1186/gb-2008-9-2-210 · 2008 · External reference
Small RNA and transcriptional upregulation
10.1002/wrna.90 · 2011 · External reference
10.1126/science.1149460
10.1126/science.1149460 · External reference
10.1016/0092-8674(93)90529-y
10.1016/0092-8674(93)90529-y · External reference
miRBase: microRNA sequences, targets and gene nomenclature
10.1093/nar/gkj112 · 2006 · External reference
10.1038/nrg2843
10.1038/nrg2843 · External reference
10.1146/annurev-pathol-012513-104715
10.1146/annurev-pathol-012513-104715 · External reference
10.1146/annurev-pharmtox-010510-100517
10.1146/annurev-pharmtox-010510-100517 · External reference
10.1073/pnas.0307323101
10.1073/pnas.0307323101 · External reference
10.1016/j.celrep.2016.03.085
10.1016/j.celrep.2016.03.085 · External reference
10.1038/nature03702
10.1038/nature03702 · External reference
10.1038/nbt1392
10.1038/nbt1392 · External reference
10.1016/j.jmoldx.2013.10.001
10.1016/j.jmoldx.2013.10.001 · External reference
Detection and characterization of placental microRNAs in maternal plasma
10.1373/clinchem.2007.097972 · 2008 · External reference
10.1111/j.1365-2141.2008.07077.x
10.1111/j.1365-2141.2008.07077.x · External reference
10.1073/pnas.0804549105
10.1073/pnas.0804549105 · External reference
The validity of circulating microRNAs in oncology: five years of challenges and contradictions
10.1016/j.molonc.2014.02.009 · 2014 · External reference
Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis
10.1111/jcmm.12353 · 2014 · External reference
10.1002/eji.201040646
10.1002/eji.201040646 · External reference
Circulating MiR-125b as a marker predicting chemoresistance in breast cancer
10.1371/journal.pone.0034210 · 2012 · External reference
Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies
10.1158/1940-6207.capr-11-0370 · 2012 · External reference
10.1073/pnas.1214046110
10.1073/pnas.1214046110 · External reference
Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs
10.1371/journal.pone.0084686 · 2014 · External reference
10.3748/wjg.v21.i34.9853
10.3748/wjg.v21.i34.9853 · External reference
10.1586/14737159.2015.980817
10.1586/14737159.2015.980817 · External reference
Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction
10.1002/ijc.29363 · 2015 · External reference
Elevated serum ribonuclease in patients with pancreatic cancer
10.1073/pnas.73.7.2308 · 1976 · External reference
10.1093/clinchem/48.10.1647
10.1093/clinchem/48.10.1647 · External reference
10.1146/annurev-cellbio-101512-122326
10.1146/annurev-cellbio-101512-122326 · External reference
10.1073/pnas.1418401112
10.1073/pnas.1418401112 · External reference
10.1038/ncb1596
10.1038/ncb1596 · External reference
10.1016/0005-2736(81)90512-5
10.1016/0005-2736(81)90512-5 · External reference
10.1016/s0021-9258(18)48095-7
10.1016/s0021-9258(18)48095-7 · External reference
10.1186/1471-2164-14-319
10.1186/1471-2164-14-319 · External reference
Diverse human extracellular RNAs are widely detected in human plasma
10.1038/ncomms11106 · 2016 · External reference
Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma
2001 · External reference
Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum
10.1093/clinchem/47.8.1488 · 2001 · External reference
10.1093/nar/gkr254
10.1093/nar/gkr254 · External reference
10.1038/ncb2210
10.1038/ncb2210 · External reference
10.1093/nar/gkq601
10.1093/nar/gkq601 · External reference
10.1073/pnas.1019055108
10.1073/pnas.1019055108 · External reference
Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid
10.3389/fgene.2013.00083 · 2013 · External reference
Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs
10.1186/1471-2164-12-435 · 2011 · External reference
10.1038/labinvest.2013.157
10.1038/labinvest.2013.157 · External reference
From benchtop to desktop: important considerations when designing amplicon sequencing workflows
10.1371/journal.pone.0124671 · 2015 · External reference
10.1200/jco.2012.45.2011
10.1200/jco.2012.45.2011 · External reference
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
10.1038/srep11198 · 2015 · External reference
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood
10.1158/1078-0432.ccr-11-2696 · 2012 · External reference
Unresolved reference
2015 · External reference
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients
10.1038/sj.onc.1207505 · 2004 · External reference
10.1016/j.ccell.2016.03.009
10.1016/j.ccell.2016.03.009 · External reference
10.1093/annonc/mdv005
10.1093/annonc/mdv005 · External reference
Circulating tumor DNA moves further into the spotlight
10.1186/gm552 · 2014 · External reference
KRAS wild-type status as detected by circulating tumor DNA analysis may be a prognostic or predictive factor for clinical benefit in patients with unresectable, locally advanced or metastatic pancreatic cancer (PC) treated with the MEK inhibitor refametin
10.1158/1538-7445.am2015-5239 · 2015 · External reference
Monitoring gastric cancer progression with circulating tumour DNA
10.1038/bjc.2014.609 · 2015 · External reference
10.1002/ijc.29265
10.1002/ijc.29265 · External reference
10.1002/ijc.29612
10.1002/ijc.29612 · External reference
10.1126/scitranslmed.aac7551
10.1126/scitranslmed.aac7551 · External reference
Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
10.1186/s12885-016-2088-5 · 2015 · External reference
10.1038/nbt.3520
10.1038/nbt.3520 · External reference
The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL
10.1016/j.molonc.2012.10.011 · 2013 · External reference
Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients
10.3892/ol.2015.3866 · 2016 · External reference
Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy
10.1038/aps.2012.125 · 2013 · External reference
Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis
10.1007/s00432-012-1285-0 · 2012 · External reference
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia
10.1182/blood-2013-01-478222 · 2013 · External reference
Circulating miR-200c and miR-141 and outcomes in patients with breast cancer
10.1186/s12885-015-1238-5 · 2015 · External reference
Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis
10.1093/carcin/bgw008 · 2016 · External reference
Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer
10.1097/sla.0b013e3182a6909d · 2014 · External reference
Examining plasma microRNA markers for colorectal cancer at different stages
10.18632/oncotarget.7196 · 2016 · External reference
Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival
10.18632/oncotarget.5766 · 2015 · External reference
Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma
2013 · External reference
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer erbitux, radiotherapy and UFT (PERU) trial
10.18632/oncotarget.7208 · 2016 · External reference
Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer
10.3892/ijo.2014.2743 · 2015 · External reference
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the GeparQuinto trial
10.1007/s10549-014-3079-3 · 2014 · External reference
10.1002/jso.23064
10.1002/jso.23064 · External reference
Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma
10.1517/14712598.2012.681373 · 2012 · External reference
Prognostic implications of serum microRNA-21 in colorectal cancer
10.1002/jso.23415 · 2013 · External reference
A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients
10.18632/oncotarget.3142 · 2015 · External reference
10.1371/journal.pone.0069239
10.1371/journal.pone.0069239 · External reference
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
10.1002/cncr.26565 · 2012 · External reference
10.1111/j.1440-1746.2010.06417.x
10.1111/j.1440-1746.2010.06417.x · External reference
10.1038/bjc.2012.546
10.1038/bjc.2012.546 · External reference
Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients
10.1007/s13277-013-1531-3 · 2014 · External reference
Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer
10.1007/s12032-014-0164-8 · 2014 · External reference
Unresolved reference
External reference
